Abstract
Purpose:
To determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography testing.
Methods:
Thirty-one eyes with choroidal neovascularization, proliferative diabetic retinopathy, and retinal vein occlusion received intravitreal bevacizumab (2.5 mg/0.1 mL). All patients underwent best-corrected visual acuity measurement, retinal fluorescein angiography, optical coherence tomography, and multifocal electroretinography at baseline and 1 month after the treatment.
Results:
Subjects undergoing multifocal electroretinography testing had no statistically significant changes in electrophysiologic responses 1 month after the intravitreal injection of bevacizumab.
Conclusion:
Multifocal electrophysiologic testing did not demonstrate any short-term cone photoreceptor toxicity after intravitreal bevacizumab.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Angiogenesis Inhibitors / adverse effects
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Bevacizumab
-
Choroidal Neovascularization / drug therapy*
-
Choroidal Neovascularization / physiopathology
-
Diabetic Retinopathy / drug therapy*
-
Diabetic Retinopathy / physiopathology
-
Electroretinography / drug effects
-
Female
-
Fluorescein Angiography
-
Humans
-
Intravitreal Injections
-
Male
-
Prospective Studies
-
Retina / physiology*
-
Retinal Vein Occlusion / drug therapy*
-
Retinal Vein Occlusion / physiopathology
-
Retreatment
-
Tomography, Optical Coherence
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Visual Acuity / physiology
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab